You just read:

Frost & Sullivan Publishes Initial Coverage Report on Kadimastem Ltd.: Kadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85.

News provided by

Frost & Sullivan

Jul 05, 2018, 09:27 ET